IsoPlexis opens first APAC office

03 February 2022 | Thursday | News

IsoPlexis Strengthens International Reach and Leadership with First APAC Office and Jason Ou as President/General Manager, APAC Region

IsoPlexis, the Superhuman Cell Company, today announced the opening of its first office in the Asia-Pacific (APAC) region headed by Jason Ou as President/General Manager, APAC Region. In this role, Mr. Ou will further advance IsoPlexis' growth in the APAC region, bolstered by a new office facility in Shanghai that will focus primarily on sales and technical support.

Mr. Ou brings more than a decade of leadership, operational, and commercial experience in the life sciences industry to IsoPlexis. He joined IsoPlexis from Tecan, a global provider of automated workflow solutions in the life science and clinical diagnostics markets. Mr. Ou started at Tecan as the OEM Components Business Manager for China & Southeast Asia, before becoming Director of OEM Business for APAC. In his last position with Tecan, Mr. Ou was Head of Market Unit Commercial Operations, Asia-Pacific.

"Jason joining our leadership team signals our commitment to growing IsoPlexis’ international footprint in the APAC region," said Peter Siesel, Chief Commercial Officer of IsoPlexis. "His extensive track record of leadership, solution-oriented thinking, and customer satisfaction in the life sciences industry all align with our plans for APAC expansion. We are confident that his leadership, along with the opening of our new office in Shanghai, will help IsoPlexis to continue its rapid global growth and innovation.”

The direct office in Shanghai, located in the New Bund Oriental Plaza Phase I, has 5000 square feet of office space dedicated to supporting the APAC commercial organization with sales, technical support, and other general operations. In addition, IsoPlexis has already opened four service labs in four of China’s largest cities: Shanghai, Beijing, Guangzhou, and Shenzhen. These service labs offer both support and test services on the IsoPlexis platform as well as demonstrations of the platform.

“IsoPlexis’ incredible single-cell proteomics technology has the potential to accelerate advanced medicines, and I’m excited and proud to be part of the journey,” said Jason Ou. “As APAC research continues to expand, I am looking forward to working with this extraordinarily talented team to bring such groundbreaking technology into the region.”


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in